Prevention of duodenal ulcer relapse by cimetidine: a one-year double-blind trial.
Fifty-one patients with duodenal ulcer which was healed by a six-week course of cimetidine completed a one-year double-blind study to compare the effects of cimetidine and placebo on the prevention of ulcer relapse. Patients were allocated at random to receive either 400 mg of cimetidine twice daily or placebo. Ulcer relapse was assessed by regular clinical follow up and endoscopy. A total of six of the 24 cimetidine-treated patients (25%) suffered a relapse compared to 25 of the 27 of placebo-treated patients (92.6%). Out of this total number of relapses, asymptomatic relapse with ulceration discovered by routine endoscopy at six months or one year, occurred in three patients receiving cimetidine and eight patients receiving placebo. Cimetidine prevents recurrence in patients with duodenal ulcer disease.
D000328:Adult; D000863:Antacids / Q000627:therapeutic use; D002927:Cimetidine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000175:diagnosis / Q000517:prevention & control*; D004724:Endoscopy; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012008:Recurrence
D000863:Antacids; D006146:Guanidines; D010919:Placebos; D002927:Cimetidine